Abstract Background Chimeric antigen receptor (CAR) T cells targeting B cell maturation antigen (BCMA) have demonstrated considerable therapeutic advantages in treating multiple my
First-in-class tri-specific T-cell engager showing promising preclinical efficacy in xenograft models, but lacks human clinical data and relies on surrogate endpoints and animal studies.